The study was supported by Novotech, Australia’s largest independent clinical contract research organization (CRO) with offices throughout Asia. 

The Frost & Sullivan research report, which will be released next month, shows that cost, regulatory speed and flexibility, and quality are the key drivers for biopharma companies selecting Australia for early phase trials. 

The report says Australia has a proven reputation with regulators including the USA FDA for quality research. 

The research highlights were presented at DIA China: 

Location: 8th DIA China Annual Meeting, China National Convention Centre, Beijing 

The research shows that Australia with its tax Incentive program can be up to 60% more cost-effective to run trials than the USA.


Watch the video recording in a new browser window:

Other relevant content